Global Cutaneous Leishmaniasis Drugs Market

Global Cutaneous Leishmaniasis Drugs Market

Global Cutaneous Leishmaniasis Drugs By Product Type, By Distribution Channel, By Geographic Scope And Forecast

According to Verified Market Research, the Global Cutaneous Leishmaniasis Drugs market was valued at USD 40.5 Million in 2018 and is projected to reach USD 56.1 Million by 2026, growing at a CAGR of 4.23% from 2019 to 2026.
Increasing healthcare spending is expected to drive the growth of cutaneous leishmaniasis market. According to the WHO, ‘spending on health is growing faster than the rest of the global economy, accounting for 10% of global gross domestic product (GDP)’. This upward trajectory of global health spending can be more definitely seen in low- and middle-income countries where health spending is growing faster than in comparison to high income countries. This can be attributed to factors such as the developing market expansion, aging and increasing populations, advances in medical treatments, urbanization and rising labor costs.
With high access barriers, the potential for the Cutaneous Leishmaniasis Drugs market is restrained as the scope for the market is confined to specific countries or regions. Addressal of the supply chain barriers in eastern Africa required consistent and specific efforts which include pooled procurement, improved forecast, and increased commitment and resources.
Based on type, the market is bifurcated into Pentavalent Antimonials, Antifungal Drugs and Anti-Leishmanial/Antimicrobial Drugs. Pentavalent Antimonials accounted for the largest market share of 39.50% in 2018 and is projected to grow at a CAGR of 4.26% during the forecast period. These drugs are known as first line drugs against cutaneous leishmaniases, however, the treatment with these drugs can cause adverse effects and is not always effective. These drugs are prescribed parenterally, daily, for at least three weeks.


1 INTRODUCTION
1.1 MARKET DEFINITION
1.2 MARKET SEGMENTATION
1.3 RESEARCH TIMELINES
1.4 ASSUMPTIONS
1.5 LIMITATIONS
2 RESEARCH METHODOLOGY
2.1 DATA MINING
2.2 SECONDARY RESEARCH
2.3 PRIMARY RESEARCH
2.4 SUBJECT MATTER EXPERT ADVICE
2.5 QUALITY CHECK
2.6 FINAL REVIEW
2.7 DATA TRIANGULATION
2.8 BOTTOM-UP APPROACH
2.9 TOP DOWN APPROACH
2.1 RESEARCH FLOW
2.11 DATA SOURCES
3 EXECUTIVE SUMMARY
3.1 MARKET OVERVIEW
3.2 GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
3.3 GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE (USD THOUSAND)
3.4 GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL (USD THOUSAND)
3.5 FUTURE MARKET OPPORTUNITIES
3.6 GLOBAL MARKET SPLIT
4 MARKET OUTLOOK
4.1 GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET OUTLOOK
4.2 MARKET DRIVERS
4.2.1 INCREASING HEALTHCARE SPENDING
4.3 MARKET RESTRAINTS
4.3.1 GLOBAL AND COUNTRY-LEVEL BARRIERS TO AN EFFECTIVE SUPPLY OF LEISHMANIASIS MEDICINES AND DIAGNOSTICS
4.4 MARKET OPPORTUNITIES
4.4.1 POTENTIAL FOR NEW LINE OF TREATMENT
4.5 MARKET CHALLENGES
4.5.1 PRESENCE OF FALSIFIED LEISHMANIASIS DRUGS
4.6 FIRST-LINE DRUGS, PATENTS, CLINICAL TRIALS & COMPOUNDS CURRENTLY UNDER PIPELINE
4.6.1 FIRST-LINE DRUGS
4.6.2 PATENTS
4.6.3 CLINICAL TRIALS
4.6.4 COMPOUNDS CURRENTLY UNDER PIPELINE
5 MARKET, BY PRODUCT TYPE
5.1 OVERVIEW
5.2 PENTAVALENT ANTIMONIALS
5.3 ANTIFUNGAL DRUGS
5.4 ANTI-LEISHMANIAL/ANTIMICROBIAL DRUGS
6 MARKET, BY DISTRIBUTION CHANNEL
6.1 OVERVIEW
6.2 HOSPITALS PHARMACIES
6.3 RETAIL PHARMACIES
6.4 ONLINE PHARMACIES
7 MARKET, BY GEOGRAPHY
7.1 OVERVIEW
7.2 NORTH AMERICA
7.2.1 U.S.
7.2.2 CANADA
7.2.3 MEXICO
7.3 EUROPE
7.3.1 GERMANY
7.3.2 FRANCE
7.3.3 U.K.
7.3.4 REST OF EUROPE
7.4 ASIA PACIFIC
7.4.1 CHINA
7.4.2 JAPAN
7.4.3 INDIA
7.4.4 REST OF ASIA PACIFIC
7.5 ROW
7.5.1 MIDDLE EAST & AFRICA
7.5.2 LATIN AMERICA
8 COMPETITIVE LANDSCAPE
8.1 OVERVIEW
8.2 COMPANY RANKING ANALYSIS
9 COMPANY PROFILES
9.1 GLAXOSMITHKLINE PLC.
9.1.1 COMPANY OVERVIEW
9.1.2 COMPANY INSIGHTS
9.1.3 SEGMENT BREAKDOWN
9.1.4 PRODUCT BENCHMARKING
9.1.5 KEY DEVELOPMENT
9.1.6 SWOT ANALYSIS
9.1 KNIGHT THERAPEUTICS INC.
9.1.1 COMPANY OVERVIEW
9.1.2 COMPANY INSIGHTS
9.1.3 PRODUCT BENCHMARKING
9.1.4 SWOT ANALYSIS
9.2 SANOFI
9.2.1 COMPANY OVERVIEW
9.2.2 COMPANY INSIGHTS
9.2.3 SEGMENT BREAKDOWN
9.2.4 PRODUCT BENCHMARKING
9.2.5 SWOT ANALYSIS
9.3 NOVARTIS AG
9.3.1 COMPANY OVERVIEW
9.3.2 COMPANY INSIGHTS
9.3.3 SEGMENT BREAKDOWN
9.3.4 PRODUCT BENCHMARKING
9.4 PFIZER INC.
9.4.1 COMPANY OVERVIEW
9.4.2 COMPANY INSIGHTS
9.4.3 SEGMENT BREAKDOWN
9.4.4 PRODUCT BENCHMARKING
9.5 JANSSEN PHARMACEUTICALS, INC.
9.5.1 COMPANY OVERVIEW
9.5.2 COMPANY INSIGHTS
9.5.3 SEGMENT BREAKDOWN
9.5.4 PRODUCT BENCHMARKING
9.6 CHEPLAPHARM ARZNEIMITTEL GMBH
9.6.1 COMPANY OVERVIEW
9.6.2 COMPANY INSIGHTS
9.6.3 PRODUCT BENCHMARKING
9.7 GLAND PHARMA LIMITED
9.7.1 COMPANY OVERVIEW
9.7.2 PRODUCT BENCHMARKING
LIST OF TABLES
TABLE 1 GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE 2017 – 2026 (USD THOUSAND)
TABLE 2 GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017 – 2026 (USD THOUSAND)
TABLE 3 GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY GEOGRAPHY, 2017 – 2026 (USD THOUSAND)
TABLE 4 NORTH AMERICA CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY COUNTRY, 2017 – 2026 (USD THOUSAND)
TABLE 5 NORTH AMERICA CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE, 2017 – 2026 (USD THOUSAND)
TABLE 6 NORTH AMERICA CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017 – 2026 (USD THOUSAND)
TABLE 7 UNITED STATES CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE, 2017 – 2026 (USD THOUSAND)
TABLE 8 UNITED STATES CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017 – 2026 (USD THOUSAND)
TABLE 9 CANADA CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE, 2017 – 2026 (USD THOUSAND)
TABLE 10 CANADA CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017 – 2026 (USD THOUSAND)
TABLE 11 MEXICO CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE, 2017 – 2026 (USD THOUSAND)
TABLE 12 MEXICO CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017 – 2026 (USD THOUSAND)
TABLE 13 EUROPE CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY COUNTRY, 2017 – 2026 (USD THOUSAND)
TABLE 14 EUROPE CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE, 2017 – 2026 (USD THOUSAND)
TABLE 15 EUROPE CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017 – 2026 (USD THOUSAND)
TABLE 16 GERMANY CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE, 2017 – 2026 (USD THOUSAND)
TABLE 17 GERMANY CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017 – 2026 (USD THOUSAND)
TABLE 18 FRANCE CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE, 2017 – 2026 (USD THOUSAND)
TABLE 19 FRANCE CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017 – 2026 (USD THOUSAND)
TABLE 20 U.K. CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE, 2017 – 2026 (USD THOUSAND)
TABLE 21 U.K. CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017 – 2026 (USD THOUSAND)
TABLE 22 REST OF EUROPE CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE, 2017 – 2026 (USD THOUSAND)
TABLE 23 REST OF EUROPE CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017 – 2026 (USD THOUSAND)
TABLE 24 ASIA PACIFIC CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY COUNTRY, 2017 – 2026 (USD THOUSAND)
TABLE 25 ASIA PACIFIC CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE, 2017 – 2026 (USD THOUSAND)
TABLE 26 ASIA PACIFIC CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017 – 2026 (USD THOUSAND)
TABLE 27 CHINA CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE, 2017 – 2026 (USD THOUSAND)
TABLE 28 CHINA CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017 – 2026 (USD THOUSAND)
TABLE 29 JAPAN CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE, 2017 – 2026 (USD THOUSAND)
TABLE 30 JAPAN CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017 – 2026 (USD THOUSAND)
TABLE 31 INDIA CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE, 2017 – 2026 (USD THOUSAND)
TABLE 32 INDIA CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017 – 2026 (USD THOUSAND)
TABLE 33 REST OF ASIA PACIFIC CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE, 2017 – 2026 (USD THOUSAND)
TABLE 34 REST OF ASIA PACIFIC CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017 – 2026 (USD THOUSAND)
TABLE 35 ROW CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY COUNTRY, 2017 – 2026 (USD THOUSAND)
TABLE 36 ROW CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE, 2017 – 2026 (USD THOUSAND)
TABLE 37 ROW CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017 – 2026 (USD THOUSAND)
TABLE 38 MIDDLE EAST & AFRICA CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE, 2017 – 2026 (USD THOUSAND)
TABLE 39 MIDDLE EAST & AFRICA CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017 – 2026 (USD THOUSAND)
TABLE 40 LATIN AMERICA CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE, 2017 – 2026 (USD THOUSAND)
TABLE 41 LATIN AMERICA CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2017 – 2026 (USD THOUSAND)
TABLE 42 GLAXOSMITHKLINE PLC.: PRODUCT BENCHMARKING
TABLE 43 GLAXOSMITHKLINE PLC.: KEY DEVELOPMENT
TABLE 44 KNIGHT THERAPEUTICS INC.: PRODUCT BENCHMARKING
TABLE 45 SANOFI: PRODUCT BENCHMARKING
TABLE 46 NOVARTIS AG: PRODUCT BENCHMARKING
TABLE 47 PFIZER INC.: PRODUCT BENCHMARKING
TABLE 48 JOHNSON & JOHNSON (JANSSEN PHARMACEUTICALS, INC.): PRODUCT BENCHMARKING
TABLE 49 CHEPLAPHARM ARZNEIMITTEL GMBH: PRODUCT BENCHMARKING
TABLE 50 GLAND PHARMA LIMITED: PRODUCT BENCHMARKING
LIST OF FIGURES
FIGURE 1 GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET SEGMENTATION
FIGURE 2 RESEARCH TIMELINES
FIGURE 3 DATA TRIANGULATION
FIGURE 4 MARKET RESEARCH FLOW
FIGURE 5 DATA SOURCES
FIGURE 6 GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET OVERVIEW
FIGURE 7 GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET GEOGRAPHICAL ANALYSIS, 2019-2026
FIGURE 8 GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE (USD THOUSAND)
FIGURE 9 GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL (USD THOUSAND)
FIGURE 10 FUTURE MARKET OPPORTUNITIES
FIGURE 11 NORTH AMERICA DOMINATED THE MARKET IN 2018
FIGURE 12 GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET OUTLOOK
FIGURE 13 GLOBAL HEALTH EXPENDITURE (% OF GDP)
FIGURE 14 GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY PRODUCT TYPE
FIGURE 15 GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY DISTRIBUTION CHANNEL
FIGURE 16 GLOBAL CUTANEOUS LEISHMANIASIS DRUGS MARKET, BY GEOGRAPHY, 2017 – 2026 (USD THOUSAND)
FIGURE 17 NORTH AMERICA MARKET SNAPSHOT
FIGURE 18 EUROPE MARKET SNAPSHOT
FIGURE 19 ASIA PACIFIC MARKET SNAPSHOT
FIGURE 20 ROW MARKET SNAPSHOT
FIGURE 21 GLAXOSMITHKLINE PLC.: COMPANY INSIGHTS
FIGURE 22 GLAXOSMITHKLINE PLC.: SEGMENT BREAKDOWN
FIGURE 23 GLAXOSMITHKLINE PLC.: SWOT ANALYSIS
FIGURE 24 KNIGHT THERAPEUTICS INC.: COMPANY INSIGHT
FIGURE 25 KNIGHT THERAPEUTICS INC.: SWOT ANALYSIS
FIGURE 26 SANOFI: COMPANY INSIGHTS
FIGURE 27 SANOFI: SEGMENT BREAKDOWN
FIGURE 28 SANOFI: SWOT ANALYSIS
FIGURE 29 NOVARTIS AG: COMPANY INSIGHTS
FIGURE 30 NOVARTIS AG: SEGMENT BREAKDOWN
FIGURE 31 PFIZER INC.: COMPANY INSIGHTS
FIGURE 32 PFIZER INC.: SEGMENT BREAKDOWN
FIGURE 33 JOHNSON & JOHNSON (JANSSEN PHARMACEUTICALS, INC.): COMPANY INSIGHTS
FIGURE 34 JOHNSON & JOHNSON (JANSSEN PHARMACEUTICALS, INC.): SEGMENT BREAKDOWN
FIGURE 35 CHEPLAPHARM ARZNEIMITTEL GMBH: COMPANY INSIGHTS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook